- Home
- ESPR
as 11-22-2024 4:00pm EST
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 456.6M | IPO Year: | 2013 |
| Target Price: | $8.17 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $3.40 | Next Earning Date: | 11-07-2024 |
| Revenue: | $295,451,000 | Revenue Growth: | 187.12% |
| Revenue Growth (this year): | 198.22% | Revenue Growth (next year): | 25.83% |
Stock Insider Trading Activity of Esperion Therapeutics Inc. (ESPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Warren Eric | ESPR | Chief Commercial Officer | Nov 19 '24 | Sell | $2.17 | 197 | $426.51 | 162,355 | |
| Warren Eric | ESPR | Chief Commercial Officer | Oct 17 '24 | Sell | $2.12 | 107 | $226.73 | 162,355 | |
| Warren Eric | ESPR | Chief Commercial Officer | Sep 17 '24 | Sell | $1.78 | 2,608 | $4,650.06 | 162,355 | |
| Koenig Sheldon L. | ESPR | President and CEO | Sep 17 '24 | Sell | $1.80 | 14,550 | $26,131.80 | 752,266 |
Latest Esperion Therapeutics Inc. News
ESPR Breaking Stock News: Dive into ESPR Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
5 days ago
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
GlobeNewswire
15 days ago
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GuruFocus.com
16 days ago
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Zacks
16 days ago
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Zacks
16 days ago
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
17 days ago
Esperion Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
17 days ago
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
Compare ESPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ESPR Esperion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.